Targeting SDF-1 in multiple myeloma tumor microenvironment

Cancer Letters

Volumn 380, Issue 1, 2016, Pages 315-318

  Bouyssou, Juliette M C ^a,b   Ghobrial, Irene M ^a   Roccaro, Aldo M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b INSERM   (France)

Author keywords

Bone marrow; CXCR4; Microenvironment; Multiple myeloma; SDF 1

Indexed keywords

4F BENZOYL TN 14003; BENDAMUSTINE; BORTEZOMIB; CHEMOKINE; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; DEXAMETHASONE; GAMBOGIC ACID; OLAPTESED PEGOL; PLERIXAFOR; RITUXIMAB; SNAKE VENOM; SORAFENIB; STROMAL CELL DERIVED FACTOR 1; THYMOQUINONE; ULOCUPLUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CXCL12 PROTEIN, HUMAN; CXCR4 PROTEIN, HUMAN;

BONE MARROW; CELL SURFACE; CHRONIC LYMPHATIC LEUKEMIA; DISEASE COURSE; HUMAN; MALIGNANT TRANSFORMATION; MULTIPLE MYELOMA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY; TUMOR CELL; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE MARROW CELL; CELL ADHESION; CELL COMMUNICATION; CELL MOTION; DRUG EFFECTS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR HYPOXIA;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; CELL ADHESION; CELL COMMUNICATION; CELL MOVEMENT; CHEMOKINE CXCL12; HUMANS; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; TUMOR HYPOXIA; TUMOR MICROENVIRONMENT;

EID: 84949651205     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.11.028     Document Type: Review

References (56)

1. [1] Möller, C., Strömberg, T., Juremalm, M., Nilsson, K., Nilsson, G., Expression and function of chemokine receptors in human multiple myeloma. Leukemia 17:1 (2003), 203–210.
2. [2] Groom, J.R., Chemokines in cellular positioning and human disease. Immunol. Cell Biol 93:4 (2015), 328–329.
3. [3] Nagasawa, T., Kikutani, H., Kishimoto, T., Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc. Natl. Acad. Sci. U.S.A. 91:6 (1994), 2305–2309.
4. [4] Nagasawa, T., CXC chemokine ligand 12 (CXCL12) and its receptor CXCR4. J. Mol. Med 92:5 (2014), 433–439.
5. [5] Shirozu, M., Nakano, T., Inazawa, J., Tashiro, K., Tada, H., Shinohara, T., et al. Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene. Genomics 28:3 (1995), 495–500.
6. [6] Yu, L., Cecil, J., Peng, S.B., Schrementi, J., Kovacevic, S., Paul, D., et al. Identification and expression of novel isoforms of human stromal cell-derived factor 1. Gene 374 (2006), 174–179.
7. [7] Ratajczak, M.Z., Zuba-Surma, E., Kucia, M., Reca, R., Wojakowski, W., Ratajczak, J., The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia 20:11 (2006), 1915–1924.
8. [8] Teicher, B.A., Fricker, S.P., CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin. Cancer Res 16:11 (2010), 2927–2931.
9. [9] Salvatore, P., Pagliarulo, C., Colicchio, R., Napoli, C., CXCR4-CXCL12-dependent inflammatory network and endothelial progenitors. Curr. Med. Chem 17:27 (2010), 3019–3029.
10. [10] Tzeng, Y.S., Li, H., Kang, Y.L., Chen, W.C., Cheng, W.C., Lai, D.M., Loss of Cxcl12/Sdf-1 in adult mice decreases the quiescent state of hematopoietic stem/progenitor cells and alters the pattern of hematopoietic regeneration after myelosuppression. Blood 117:2 (2011), 429–439.
11. [11] Hideshima, T., Chauhan, D., Hayashi, T., Podar, K., Akiyama, M., Gupta, D., et al. The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Mol. Cancer Ther 1:7 (2002), 539–544.
12. [12] Alsayed, Y., Ngo, H., Runnels, J., Leleu, X., Singha, U.K., Pitsillides, C.M., et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 109:7 (2007), 2708–2717.
13. [13] Chatterjee, S., Behnam Azad, B., Nimmagadda, S., The intricate role of CXCR4 in cancer. Adv. Cancer Res 124 (2014), 31–82.
14. [14] Tarnowski, M., Liu, R., Wysoczynski, M., Ratajczak, J., Kucia, M., Ratajczak, M.Z., CXCR7: a new SDF-1-binding receptor in contrast to normal CD34(+) progenitors is functional and is expressed at higher level in human malignant hematopoietic cells. Eur. J. Haematol 85:6 (2010), 472–483.
15. [15] Azab, A.K., Sahin, I., Moschetta, M., Mishima, Y., Burwick, N., Zimmermann, J., et al. CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma. Blood 18:12 (2014), 1905–1914.
16. [16] Röllig, C., Knop, S., Bornhäuser, M., Multiple myeloma. Lancet 385:9983 (2015), 2197–2208.
17. [17] Manier, S., Sacco, A., Leleu, X., Ghobrial, I.M., Roccaro, A.M., Bone marrow microenvironment in multiple myeloma progression. J. Biomed. Biotechnol, 2012, 2012, 157496.
18. [18] Kawano, Y., Moschetta, M., Manier, S., Glavey, S., Görgün, G.T., Roccaro, A.M., et al. Targeting the bone marrow microenvironment in multiple myeloma. Immunol. Rev 263:1 (2015), 160–172.
19. [19] Romano, A., Conticello, C., Cavalli, M., Vetro, C., La Fauci, A., Parrinello, N.L., et al. Immunological dysregulation in multiple myeloma microenvironment. Biomed Res. Int, 2014, 2014, 198539.
20. [20] Toscani, D., Bolzoni, M., Accardi, F., Aversa, F., Giuliani, N., The osteoblastic niche in the context of multiple myeloma. Ann. N. Y. Acad. Sci 1335 (2015), 45–62.
21. [21] Ribatti, D., Moschetta, M., Vacca, A., Microenvironment and multiple myeloma spread. Thromb. Res 133:Suppl. 2 (2014), S102–S106.
22. [22] Roccaro, A.M., Sacco, A., Purschke, W.G., Moschetta, M., Buchner, K., Maasch, C., et al. SDF-1 inhibition targets the bone marrow niche for cancer therapy. Cell Rep 9:1 (2014), 118–128.
23. [23] Parmo-Cabañas, M., Molina-Ortiz, I., Matías-Román, S., García-Bernal, D., Carvajal-Vergara, X., Valle, I., et al. Role of metalloproteinases MMP-9 and MT1-MMP in CXCL12-promoted myeloma cell invasion across basement membranes. J. Pathol 208:1 (2006), 108–118.
24. [24] Menu, E., Asosingh, K., Indraccolo, S., De Raeve, H., Van Riet, I., Van Valckenborgh, E., et al. The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model. Haematologica 91:5 (2006), 605–612.
25. [25] Parmo-Cabañas, M., Bartolomé, R.A., Wright, N., Hidalgo, A., Drager, A.M., Teixidó, J., Integrin alpha4beta1 involvement in stromal cell-derived factor-1alpha-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion. Exp. Cell Res 294:2 (2004), 571–580.
26. [26] Sanz-Rodríguez, F., Hidalgo, A., Teixidó, J., Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood 97:2 (2001), 346–351.
27. [27] García-Bernal, D., Redondo-Muñoz, J., Dios-Esponera, A., Chèvre, R., Bailón, E., Garayoa, M., et al. Sphingosine-1-phosphate activates chemokine-promoted myeloma cell adhesion and migration involving α4β1 integrin function. J. Pathol 229:1 (2013), 36–48.
28. [28] Wright, N., de Lera, T.L., García-Moruja, C., Lillo, R., García-Sánchez, F., Caruz, A., et al. Transforming growth factor-beta1 down-regulates expression of chemokine stromal cell-derived factor-1: functional consequences in cell migration and adhesion. Blood 102:6 (2003), 1978–1984.
29. [29] Rø, T.B., Holien, T., Fagerli, U.M., Hov, H., Misund, K., Waage, A., et al. HGF and IGF-1 synergize with SDF-1α in promoting migration of myeloma cells by cooperative activation of p21-activated kinase. Exp. Hematol 41:7 (2013), 646–655.
30. [30] de Gorter, D.J., Reijmers, R.M., Beuling, E.A., Naber, H.P., Kuil, A., Kersten, M.J., et al. The small GTPase Ral mediates SDF-1-induced migration of B cells and multiple myeloma cells. Blood 111:7 (2008), 3364–3372.
31. [31] Azab, A.K., Azab, F., Blotta, S., Pitsillides, C.M., Thompson, B., Runnels, J.M., et al. RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. Blood 114:3 (2009), 619–629.
32. [32] Martin, S.K., Dewar, A.L., Farrugia, A.N., Horvath, N., Gronthos, S., To, L.B., et al. Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1alpha in patients with multiple myeloma. Clin. Cancer Res 12:23 (2006), 6973–6977.
33. [33] Pellegrino, A., Ria, R., Di Pietro, G., Cirulli, T., Surico, G., Pennisi, A., et al. Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells. Br. J. Haematol 129:2 (2005), 248–256.
34. [34] Martin, S.K., Diamond, P., Williams, S.A., To, L.B., Peet, D.J., Fujii, N., et al. Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. Haematologica 95:5 (2010), 776–784.
35. [35] Kim, S.W., Kim, H.Y., Lee, H.J., Yun, H.J., Kim, S., Jo, D.Y., Dexamethasone and hypoxia upregulate CXCR4 expression in myeloma cells. Leuk. Lymphoma 50:7 (2009), 1163–1173.
36. [36] Moschetta, M., Mishima, Y., Sahin, I., Manier, S., Glavey, S., Vacca, A., et al. Role of endothelial progenitor cells in cancer progression. Biochim. Biophys. Acta 1846:1 (2014), 26–39.
37. [37] Moschetta, M., Mishima, Y., Kawano, Y., Aljawai, Y., Paiva, B., Palomera, L., et al. Early trafficking of bone marrow derived-endothelial progenitor cells promotes multiple myeloma progression. 56th American Society of Hematology Annual Meeting and Exposition, San Francisco, 2014, 4719.
38. [38] Zannettino, A.C., Farrugia, A.N., Kortesidis, A., Manavis, J., To, L.B., Martin, S.K., et al. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res 65:5 (2005), 1700–1709.
39. [39] Diamond, P., Labrinidis, A., Martin, S.K., Farrugia, A.N., Gronthos, S., To, L.B., et al. Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss. J. Bone Miner. Res 24:7 (2009), 1150–1161.
40. [40] Bam, R., Ling, W., Khan, S., Pennisi, A., Venkateshaiah, S.U., Li, X., et al. Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease. Am. J. Hematol 88:6 (2013), 463–471.
41. [41] Beider, K., Bitner, H., Leiba, M., Gutwein, O., Koren-Michowitz, M., Ostrovsky, O., et al. Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype. Oncotarget 5:22 (2014), 11283–11296.
42. [42] Frassanito, M.A., Rao, L., Moschetta, M., Ria, R., Di Marzo, L., De Luisi, A., et al. Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies. Leukemia 28:4 (2014), 904–916.
43. [43] Keating, G.M., Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma. Drugs 71:12 (2011), 1623–1647.
44. [44] Azab, A.K., Runnels, J.M., Pitsillides, C., Moreau, A.S., Azab, F., Leleu, X., et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 113:18 (2009), 4341–4351.
45. [45] Hoellenriegel, J., Zboralski, D., Maasch, C., Rosin, N.Y., Wierda, W.G., Keating, M.J., et al. The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. Blood 123:7 (2014), 1032–1039.
46. [46] Badr, G., Al-Sadoon, M.K., Abdel-Maksoud, M.A., Rabah, D.M., El-Toni, A.M., Cellular and molecular mechanisms underlie the anti-tumor activities exerted by Walterinnesia aegyptia venom combined with silica nanoparticles against multiple myeloma cancer cell types. PLoS ONE, 7(12), 2012, e51661.
47. [47] Al-Sadoon, M.K., Rabah, D.M., Badr, G., Enhanced anticancer efficacy of snake venom combined with silica nanoparticles in a murine model of human multiple myeloma: molecular targets for cell cycle arrest and apoptosis induction. Cell. Immunol 284:1–2 (2013), 129–138.
48. [48] Badr, G., Lefevre, E.A., Mohany, M., Thymoquinone inhibits the CXCL12-induced chemotaxis of multiple myeloma cells and increases their susceptibility to Fas-mediated apoptosis. PLoS ONE, 6(9), 2011, e23741.
49. [49] Udi, J., Schüler, J., Wider, D., Ihorst, G., Catusse, J., Waldschmidt, J., et al. Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization. Br. J. Haematol 161:1 (2013), 104–116.
50. [50] Kuhne, M.R., Mulvey, T., Belanger, B., Chen, S., Pan, C., Chong, C., et al. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin. Cancer Res 19:2 (2013), 357–366.
51. [51] Beider, K., Begin, M., Abraham, M., Wald, H., Weiss, I.D., Wald, O., et al. CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. Exp. Hematol 39:3 (2011), 282–292.
52. [52] Scala, S., Molecular pathways: targeting the CXCR4-CXCL12 axis-untapped potential in the tumor microenvironment. Clin. Cancer Res 21:19 (2015), 4278–4285.
53. [53] Pandey, M.K., Kale, V.P., Song, C., Sung, S.S., Sharma, A.K., Talamo, G., et al. Gambogic acid inhibits multiple myeloma mediated osteoclastogenesis through suppression of chemokine receptor CXCR4 signaling pathways. Exp. Hematol 42:10 (2014), 883–896.
54. [54] Oliveira, A.M., Maria, D.A., Metzger, M., Linardi, C., Giorgi, R.R., Moura, F., et al. Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients. Leuk. Res 33:7 (2009), 970–973.
55. [55] Mirandola, L., Apicella, L., Colombo, M., Yu, Y., Berta, D.G., Platonova, N., et al. Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1. Leukemia 27:7 (2013), 1558–1566.
56. [56] Kumar, S.K., Dispenzieri, A., Lacy, M.Q., Gertz, M.A., Buadi, F.K., Pandey, S., et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28:5 (2014), 1122–1128.